Home > Boards > US OTC > Biotechs > NorthWest Biotherapeutics Inc. (NWBO)

UPDATE 10/17/21: Speculation as to what happens

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
ae kusterer Member Profile
 
Followed By 39
Posts 2,288
Boards Moderated 0
Alias Born 02/27/16
160x600 placeholder
Northwest Biotherapeutics secures $15M financing on stock purchase rights Seeking Alpha - 11/29/2021 11:11:27 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/15/2021 4:41:30 PM
IQST Has Catalysts On Deck That Expose A Valuation Disconnect of Roughly 100% - Here's Why That Gap Should Close InvestorsHub NewsWire - 11/5/2021 10:20:59 AM
iQSTEL, Inc. - The Calm Before The Surge (OTCQX: IQST) InvestorsHub NewsWire - 10/29/2021 2:31:48 PM
Star Alliance Intl. Corp. (OTC Pink: STAL) Recent Gold Mine Acquisition NI43-101 InvestorsHub NewsWire - 10/29/2021 7:08:34 AM
IQST - EV & Hi-Tech Company Poised For Potential 4X ROI - Q3 Financials and Short Squeeze InvestorsHub NewsWire - 10/14/2021 11:34:44 AM
CEO Presenting on the Emerging Growth Conference on October 13 Register Now InvestorsHub NewsWire - 10/11/2021 7:00:00 AM
CLS Holdings, (OTCQB: CLSH) New Joint Venture $19 million Sales 61% Growth InvestorsHub NewsWire - 9/28/2021 7:24:31 AM
CEO Presenting on the Emerging Growth Conference on September 29  Register Now InvestorsHub NewsWire - 9/27/2021 8:35:40 AM
CEO Presenting on the Emerging Growth Conference Tomorrow.  Register Now InvestorsHub NewsWire - 9/14/2021 7:00:00 AM
CEO Presenting on the Emerging Growth Conference on September 15.  Register Now InvestorsHub NewsWire - 9/13/2021 7:00:00 AM
CEO Presenting on the Emerging Growth Conference on September 1.  Register Now InvestorsHub NewsWire - 8/31/2021 7:00:00 AM
CLS Holdings, (OTCQB: CLSH) July Sales $1.9 Million 104% increase over July 2019 InvestorsHub NewsWire - 8/17/2021 7:21:24 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/16/2021 4:41:47 PM
CEO Presenting on the Emerging Growth Conference on August 4.  Register Now InvestorsHub NewsWire - 8/3/2021 7:00:00 AM
WSGF - World Series of Golf Inc VERY BULLISH Signal Continues InvestorsHub NewsWire - 8/2/2021 9:45:22 AM
CEO Presenting on the First Emerging Growth / Investors Hub Joint Conference on July 21 InvestorsHub NewsWire - 7/19/2021 7:00:00 AM
CEO Presenting on the Emerging Growth / Investors Hub Joint Conference Tomorrow.  Register Now InvestorsHub NewsWire - 7/6/2021 7:00:00 AM
Sino United (OTC Pink: SUIC) $200 Million Commitment, Signs with Suntech, the Largest Taiwan O2O Company. InvestorsHub NewsWire - 6/30/2021 7:30:00 AM
CEO Presenting on the First Emerging Growth / Investors Hub Joint Conference Tomorrow!  Register Now InvestorsHub NewsWire - 6/22/2021 7:00:00 AM
CEO's Presenting at Emerging Growth Conference Virtually This Week InvestorsHub NewsWire - 6/7/2021 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/24/2021 4:35:22 PM
Northwest Bio gaining attention as investors await phase 3 GBM data Seeking Alpha - 5/24/2021 11:16:44 AM
CEO's Presenting at Emerging Growth Conference Virtually This Week InvestorsHub NewsWire - 5/24/2021 7:03:10 AM
IQST Signals BUY InvestorsHub NewsWire - 5/20/2021 9:43:19 AM
ae kusterer   Sunday, 10/17/21 02:38:32 PM
Re: None
Post # of 424544 
UPDATE 10/17/21: Speculation as to what happens between now and SNO, 11/18/21.(This alphavestcapital.com commentary was first published at the comment site of a recent Seeking Alpha blog post on NWBO (link below) .



(https://seekingalpha.com/instablog/48206531-scottyz177/5650628-northwest-bio-imminent-catalysts-highly-compelling-upside-significant-improvement-to-brain)



An appropriate valuation of NWBO can be addressed one way as just a question of math: Dc Vax L for GBM alone should generate $3-5 billion in revenues(25,000 plus new cases annually) . Revenues from 13 solid tumors should be $3.9 billion, and revenues from 10 combination therapies with Keytruda (MRK) should be $2.5 billion .That’s roughly $10 billion. Proprietary vaccines, with a 90% manufacturing margin, commonly get valued at 10x revenues.So getting to a $100 billion market cap is conceivable.
What about the current stock price? The stock at $1.29 represents a $1.7 billion valuation. At at 12/31/20, the stock was $1.40.Since then there’s been alot of derisking:
1)The U.K.MHRA certification appears to be days/weeks away. Such certification amounts to a stealth commercial approval for the U.K. Patients that can get DC vax L per month increases from 4 to 45($100 million in annual revenues).If all goes well for a year, the patients served per month is scheduled to increase to 500, or $1 billion in revenues annually.
2) The FDA appears to be on out ahead of NWBO endorsing the use of external controls.
3)Cognate, NWBO’s North American contract manufacturer, has been bought by CRL, a world class biologic manufacturer .
4) In recent months,NWBO’s lead investigators(Liau, Ashkan, Cloughesy, Quinones-Hinajosa) have endorsed the satiety and efficacy of DC Vax L. On May 2, 2021, Dr.Ashkan updated the 6/1/18 blinded data study, stating that 1/3 of the patients were living 7-8 years.SOC treated patients live 16.3 months on average.


https://open.spotify.com/episode/68Dkypq2S27mN2e03wWFt

whttps://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6



So, what’s holding NWBO ’s stock down?
1)A reclusive, very non promotional, CEO,
2) An OTC markets listing;therfore NWBO is not a “listed “stock.
3)The listing , and sparse cash, and unrevealed phase 3 trail data, makes the stock institutionally noninvestible .
4)Other things holding stock down: no research coverage because they don’t take investment banking services. Also, funds that are holding the stock generally don’t file 13-F’s disclosing holdings for OTC traded companies.
WHY IS NWBO A BARGAIN ?
1) A stealth commercial approval is within days of being granted the the U.K.’s MHRA.
2)A series of positives are about to be announced at and leading up to a major near-oncology conference:
a)a scientific publication of NWBO’s phase 3 trial.
b)multiple presentations at the upcoming conference by the trial’s lead investigators.
c) there have been hints that the UCLA-Keytruda-Dc Vax l combo trial is a success.


3) Nwbo has annual revenue potential of $2-10 billion.That’s free cash flow of $1-8 billion annually for 10 years.A 20x free cash flow multiple could be realized.


4) The accuracy of the above valuation potentials for NWBO will be validated, or not, by what large Pharma /Biotech companies are will to bid for NWBO, post scientific publication. Discounted for the present value of future cash flows, the bid sizes will most like be 50% of the AVC(alphavestcapital.com #7 Model Portfolio) stated values.





Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences